Miraculins Executes Agreement for the Sale and Distribution of Up to $90 Million USD in Scout DS® Diabetes Screening Devices in China - Seite 2

The Agreement outlines the terms and conditions, including Scout DS^® device unit pricing, upfront and milestone payments, product ordering and diligence requirements, and ongoing responsibilities of the parties.

Key terms of the Agreement include:

• The term of the Agreement is to extend for five years from the date of procurement of CFDA (Chinese Food and Drug Administration) regulatory clearance of the Scout DS^® device, subject to minimum Scout DS^® device sales orders being met;

• Miraculins to receive certain upfront and milestone payments;

• Initial minimum guaranteed order for $15 Million USD in Scout DS^® devices for the first year of the term, confirmed on execution of the Agreement, and to be activated on procurement of CFDA regulatory clearance of the Scout DS^® device;

• Subsequent minimum orders for $15 Million USD in Scout DS^® devices for each of years two, three and four of the term, totalling $45 Million USD;

• Subsequent minimum order for $30 Million USD in Scout DS^® devices in year five of the term;

• Miraculins to be responsible for leading the CFDA regulatory clearance process and its related costs, with Cachet providing guidance and support as necessary;

• Miraculins to retain the right to establish programs for ongoing device servicing and maintenance once the Scout DS^® devices are sold into the field.

The Scout DS^® device has received regulatory clearance in Canada and is CE marked throughout the European Union, and Miraculins has recently filed pre-submission documentation with the USFDA (United States Food and Drug Administration) towards securing Scout DS^® device marketing clearance in the United States.

About Cachet Pharmaceutical Co., Ltd.

Founded in 1998, Cachet Pharmaceutical Co., Ltd. is a majority state-owned stock company with a market capitalization of 4 Billion RMB (or about $655 Million USD). Cachet's largest shareholder, the China Youth Industrial Development Corporation, is owned directly by the Central Committee of the Communist Youth League of China. On August 18, 2010, Cachet went public on the Shenzhen Stock Exchange (stock name: Cachet; stock code: 002462). Cachet Pharmaceutical Co., Ltd. engages in the wholesale and retail sale of pharmaceutical products in China including brands such as Bayer, Novartis, Johnson & Johnson, and Medtronic. The company is involved in the supply of medicines to hospitals; wholesale of biological products, medical instruments, and traditional Chinese medicines; and pharmaceutical logistics. It additionally owns 150 chain stores in Beijing that sell medicines, healthcare food, medical instruments, cosmetics, daily necessities, and traditional Chinese medicines.